Bacterial munch for infants: Potential pediatric therapeutic interventions of probiotics

Future Microbiology

Volumn 10, Issue 11, 2015, Pages 1881-1895

  Khurshid, Mohsin ^a   Aslam, Bilal ^a   Nisar, Muhammad Atif ^a   Akbar, Rubab ^b   Rahman, Hazir ^c   Khan, Abdul Arif ^d   Rasool, Muhammad Hidayat ^a  

^a GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

^b NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

^c KOHAT UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Pakistan)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Bifidobacteria; clinical trials; metagenome; microbiota; necrotizing enterocolitis

Indexed keywords

PROBIOTIC AGENT;

ARTIFICIAL MILK; ATOPIC DERMATITIS; BREAST FEEDING; DIARRHEA; DIGESTION; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; INFANT DISEASE; INFANT FEEDING; INFANTILE COLIC; INTESTINE FLORA; NECROTIZING ENTEROCOLITIS; NEWBORN SEPSIS; NONALCOHOLIC FATTY LIVER; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); GASTROINTESTINAL DISEASES; INFANT; MICROFLORA; NEWBORN; ORAL DRUG ADMINISTRATION; PROCEDURES; REPRODUCIBILITY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; HUMANS; INFANT; INFANT, NEWBORN; MICROBIOTA; PROBIOTICS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84948143544     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.102     Document Type: Review

References (106)

1. Vanderhoof JA, Young R. Probiotics in the United States. Clin. Infect. Dis. 46(Suppl. 2), S67-S72; discussion S144-S151 (2008).
2. Khan AA, Shrivastava A, Khurshid M. Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochim. Biophys. Acta 1826(2), 331-337 (2012).
3. Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin. Infect. Dis. 46(Suppl. 2), S96-S100; discussion S144-S151 (2008).
4. Holzapfel WH, Schillinger U. Introduction to pre-and probiotics. Food Res. Int. 35(2), 109-116 (2002).
5. Braegger C, Chmielewska A, Decsi T et al. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J. Pediatr. Gastroenterol. Nutr. 52(2), 238-250 (2011).
6. Matamoros S, Gras-Leguen C, Le Vacon F, Potel G, De La Cochetiere MF. Development of intestinal microbiota in infants and its impact on health. Trends Microbiol. 21(4), 167-173 (2013).
7. Jimenez E, Fernandez L, Marin ML et al. Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr. Microbiol. 51(4), 270-274 (2005).
8. Digiulio DB, Romero R, Amogan HP et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS ONE 3(8), e3056 (2008).
9. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J. Pediatr. Gastroenterol. Nutr. 30(1), 61-67 (2000).
10. Turroni F, Peano C, Pass DA et al. Diversity of bifidobacteria within the infant gut microbiota. PLoS ONE 7(5), e36957 (2012).
11. Aires J, Thouverez M, Allano S, Butel MJ. Longitudinal analysis and genotyping of infant dominant bifidobacterial populations. Syst. Appl. Microbiol. 34(7), 536-541 (2011).
12. Penders J, Thijs C, Vink C et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 118(2), 511-521 (2006).
13. Balmer SE, Wharton BA. Diet and faecal flora in the newborn: breast milk and infant formula. Arch. Dis. Child 64(12), 1672-1677 (1989).
14. Stark PL, Lee A. The microbial ecology of the large bowel of breast-fed and formula-fed infants during the first year of life. J. Med. Microbiol. 15(2), 189-203 (1982).
15. Panigrahi P. Probiotics and prebiotics in neonatal necrotizing enterocolitis: new opportunities for translational research. Pathophysiology 21(1), 35-46 (2014).
16. Long SS, Swenson RM. Development of anaerobic fecal flora in healthy newborn infants. J. Pediatr. 91(2), 298-301 (1977).
17. Adlerberth I, Wold AE. Establishment of the gut microbiota in eestern infants. Acta Paediatr. 98(2), 229-238 (2009).
18. Di Mauro A, Neu J, Riezzo G et al. Gastrointestinal function development and microbiota. Ital J. Pediatr. 39 15 (2013).
19. Agostoni C, Braegger C, Decsi T et al. Breast-feeding: a commentary by the ESPGHAN Committee on Nutrition. J. Pediatr. Gastroenterol. Nutr. 49(1), 112-125 (2009).
20. Vlieger AM, Robroch A, Van Buuren S et al. Tolerance and safety of Lactobacillus paracasei ssp. paracasei in combination with Bifidobacterium animalis ssp. lactis in a prebiotic-containing infant formula: a randomised controlled trial. Br. J. Nutr. 102(6), 869-875 (2009).
21. Solis G, De Los Reyes-Gavilan CG, Fernandez N, Margolles A, Gueimonde M. Establishment and development of lactic acid bacteria and bifidobacteria microbiota in breast-milk and the infant gut. Anaerobe 16(3), 307-310 (2010).
22. Mugambi MN, Musekiwa A, Lombard M, Young T, Blaauw R. Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review. Nutr. J. 11, 81 (2012).
23. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics 126(6), 1217-1231 (2010).
24. Bullen CL, Tearle PV, Willis AT. Bifidobacteria in the intestinal tract of infants: an in-vivo study. J. Med. Microbiol. 9(3), 325-333 (1976).
25. Lundequist B, Nord CE, Winberg J. The composition of the faecal microflora in breastfed and bottle fed infants from birth to eight weeks. Acta Paediatr. Scand 74(1), 45-51 (1985).
26. Newburg DS. Neonatal protection by an innate immune system of human milk consisting of oligosaccharides and glycans. J. Anim. Sci. 87(13 Suppl.), 26-34 (2009).
27. Zagato E, Mileti E, Massimiliano L et al. Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo. PLoS ONE 9(2), e87615 (2014).
28. Riva E, Verduci E, Agostoni C, Giovannini M. Closer to the gold standard: an appraisal of formulae available in Italy for use in formula-fed infants. J. Int. Med. Res. 33(6), 595-611 (2005).
29. Kent RM, Doherty SB. Probiotic bacteria in infant formula and follow-up formula: microencapsulation using milk and pea proteins to improve microbiological quality. Food Res. Int. 64 567-576 (2014).
30. Charteris WP, Kelly PM, Morelli L, Collins JK. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J. Appl. Microbiol. 84(5), 759-768 (1998).
31. Kailasapathy K. Microencapsulation of probiotic bacteria: technology and potential applications. Curr. Issues Intest. Microbiol. 3(2), 39-48 (2002).
32. Cook MT, Tzortzis G, Charalampopoulos D, Khutoryanskiy VV. Microencapsulation of probiotics for gastrointestinal delivery. J. Control. Release 162(1), 56-67 (2012).
33. Solanki HK, Pawar DD, Shah DA et al. Development of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agent. BioMed Res. Int. 2013 620719 (2013).
34. Hansen LT, Allan-Wojtas P, Jin Y-L, Paulson A. Survival of Ca-alginate microencapsulated Bifidobacterium spp. in milk and simulated gastrointestinal conditions. Food Microbiol. 19(1), 35-45 (2002).
35. Krasaekoopt W, Bhandari B, Deeth H. Evaluation of encapsulation techniques of probiotics for yoghurt. Int. Dairy J. 13(1), 3-13 (2003).
36. Ohland CL, MacNaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 298(6), G807-G819 (2010).
37. Ashida H, Ogawa M, Kim M, Mimuro H, Sasakawa C. Bacteria and host interactions in the gut epithelial barrier. Nat. Chem. Biol. 8(1), 36-45 (2011).
38. Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc. Natl Acad. Sci. USA 99(24), 15451-15455 (2002).
39. Indrio F, Riezzo G, Cavallo L, Di Mauro A, Francavilla R. Physiological basis of food intolerance in VLBW. J. Matern. Fetal Neonatal Med. 24(Suppl. 1), 64-66 (2011).
40. Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek 70(2-4), 347-358 (1996).
41. Khan AA, Khurshid M, Khan S, Alshamsan A. Gut microbiota and probiotics: current status and their role in cancer therapeutics. Drug Dev. Res. 74(6), 365-375 (2013).
42. Fukushima Y, Kawata Y, Hara H, Terada A, Mitsuoka T. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int. J. Food Microbiol. 42(1-2), 39-44 (1998).
43. Hunt KM, Foster JA, Forney LJ et al. Characterization of the diversity and temporal stability of bacterial communities in human milk. PLoS ONE 6(6), e21313 (2011).
44. Bauer E, Williams BA, Smidt H, Verstegen MW, Mosenthin R. Influence of the gastrointestinal microbiota on development of the immune system in young animals. Curr. Issues Intest. Microbiol. 7(2), 35-51 (2006).
45. Tsai YT, Cheng PC, Pan TM. The immunomodulatory effects of lactic acid bacteria for improving immune functions and benefits. Appl. Microbiol. Biotechnol. 96(4), 853-862 (2012).
46. Lammers KM, Brigidi P, Vitali B et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol. Med. Microbiol. 38(2), 165-172 (2003).
47. Holscher HD, Czerkies LA, Cekola P et al. Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial. JPEN J. Parenter. Enteral. Nutr. 36(1 Suppl.), 106S-117S (2012).
48. Agostoni C, Goulet O, Kolacek S et al. Fermented infant formulae without live bacteria. J. Pediatr. Gastroenterol. Nutr. 44(3), 392-397 (2007).
49. Esposito S, Rigante D, Principi N. Do children's upper respiratory tract infections benefit from probiotics BMC Infect. Dis. 14, 194 (2014).
50. Vouloumanou EK, Makris GC, Karageorgopoulos DE, Falagas ME. Probiotics for the prevention of respiratory tract infections: a systematic review. Int. J. Antimicrob. Agents 34(3), 197 e191-110 (2009).
51. Santagati M, Scillato M, Patane F, Aiello C, Stefani S. Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol. Med. Microbiol. 65(1), 23-31 (2012).
52. Gao Z, Kang Y, Yu J, Ren L. Human pharyngeal microbiome may play a protective role in respiratory tract infections. Genomics Proteomics Bioinformatics 12(3), 144-150 (2014).
53. Szajewska H. Probiotics and prebiotics in preterm infants: where are we Where are we going Early Hum. Dev. 86(Suppl. 1), 81-86 (2010).
54. Llanos AR, Moss ME, Pinzon MC, Dye T, Sinkin RA, Kendig JW. Epidemiology of neonatal necrotising enterocolitis: a population-based study. Paediatr. Perinat. Epidemiol. 16(4), 342-349 (2002).
55. Bernardo WM, Aires FT, Carneiro RM, Sa FP, Rullo VE, Burns DA. Effectiveness of probiotics in the prophylaxis of necrotizing enterocolitis in preterm neonates: a systematic review and meta-analysis. J. Pediatr. (Rio J.) 89(1), 18-24 (2013).
56. Claud EC. Probiotics and neonatal necrotizing enterocolitis. Anaerobe 17(4), 180-185 (2011).
57. Indrio F, Riezzo G, Raimondi F, Bisceglia M, Cavallo L, Francavilla R. The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J. Pediatr. 152(6), 801-806 (2008).
58. Abrahamsson TR, Rautava S, Moore AM, Neu J, Sherman PM. The time for a confirmative necrotizing enterocolitis probiotics prevention trial in the extremely low birth weight infant in North America is now! J. Pediatr. 165(2), 389-394 (2014).
59. Sung V, Hiscock H, Tang ML et al. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ 348, g2107 (2014).
60. Rhoads JM, Fatheree NY, Norori J et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. J. Pediatr. 155(6), 823-828 e821 (2009).
61. Grzeskowiak L, Gronlund MM, Beckmann C, Salminen S, Von Berg A, Isolauri E. The impact of perinatal probiotic intervention on gut microbiota: double-blind placebocontrolled trials in Finland and Germany. Anaerobe 18(1), 7-13 (2012).
62. Savino F, Cordisco L, Tarasco V et al. Antagonistic effect of Lactobacillus strains against gas-producing coliforms isolated from colicky infants. BMC Microbiol. 11, 157 (2011).
63. Indrio F, Riezzo G, Raimondi F et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur. J. Clin. Invest. 41(4), 417-422 (2011).
64. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J. Pediatr. 162(2), 257-262 (2013).
65. Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am. J. Clin. Nutr. 79(2), 261-267 (2004).
66. Yang M, Gong S, Ye SQ et al. Non-alcoholic fatty liver disease in children: focus on nutritional interventions. Nutrients 6(11), 4691-4705 (2014).
67. Mitchel EB, Lavine JE. Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 40(10), 1155-1170 (2014).
68. Vajro P, Mandato C, Licenziati MR et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr. 52(6), 740-743 (2011).
69. Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 10(5), 889-902 (2015).
70. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J. Allergy Clin. Immunol. 99(2), 179-185 (1997).
71. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357(9262), 1076-1079 (2001).
72. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin. Exp. Allergy 30(11), 1604-1610 (2000).
73. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J. Pediatr. Gastroenterol. Nutr. 36(2), 223-227 (2003).
74. Penders J, Stobberingh EE, Van Den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. Allergy 62(11), 1223-1236 (2007).
75. Doron S, Snydman DR, Gorbach SL. Lactobacillus GG: bacteriology and clinical applications. Gastroenterol. Clin. North Am. 34(3), 483-498, ix (2005).
76. Winkler P, Ghadimi D, Schrezenmeir J, Kraehenbuhl JP. Molecular and cellular basis of microflora-host interactions. J. Nutr. 137(3 Suppl. 2), 756S-772S (2007).
77. Matsumoto M, Aranami A, Ishige A, Watanabe K, Benno Y. LKM512 yogurt consumption improves the intestinal environment and induces the T-helper type 1 cytokine in adult patients with intractable atopic dermatitis. Clin. Exp. Allergy 37(3), 358-370 (2007).
78. Passeron T, Lacour JP, Fontas E, Ortonne JP. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy 61(4), 431-437 (2006).
79. Baquerizo Nole KL, Yim E, Keri JE. Probiotics and prebiotics in dermatology. J. Am. Acad. Dermatol. 71(4), 814-821 (2014).
80. Manzoni P. Use of Lactobacillus casei subspecies Rhamnosus GG and gastrointestinal colonization by Candida species in preterm neonates. J. Pediatr. Gastroenterol. Nutr. 45(Suppl. 3), S190-S194 (2007).
81. Kumar S, Singhi S. Role of probiotics in prevention of Candida infection in critically ill children. Mycoses 56(3), 204-211 (2013).
82. Khan AA, Cash P. E. coli and colon cancer: is mutY a culprit Cancer Lett. 341(2), 127-131 (2013).
83. Raza S, Graham SM, Allen SJ, Sultana S, Cuevas L, Hart CA. Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan. Pediatr. Infect. Dis. J. 14(2), 107-111 (1995).
84. Szymanski H, Pejcz J, Jawien M, Chmielarczyk A, Strus M, Heczko PB. Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains-a randomized, double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther. 23(2), 247-253 (2006).
85. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J. Pediatr. 138(3), 361-365 (2001).
86. Rautava S. Potential uses of probiotics in the neonate. Semin. Fetal Neonatal Med. 12(1), 45-53 (2007).
87. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 115(1), 5-9 (2005).
88. Salazar-Lindo E, Miranda-Langschwager P, Campos-Sanchez M, Chea-Woo E, Sack RB. Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]. BMC Pediatr. 4, 18 (2004).
89. Guandalini S. Probiotics for children: use in diarrhea. J. Clin. Gastroenterol. 40(3), 244-248 (2006).
90. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks Am. J. Clin. Nutr. 83(6), 1256-1264 (2006).
91. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J. Pediatr. Gastroenterol. Nutr. 38(4), 457-458 (2004).
92. Wagner RD, Pierson C, Warner T et al. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect. Immun. 65(10), 4165-4172 (1997).
93. Young SL, Simon MA, Baird MA et al. Bifidobacterial species differentially affect expression of cell surface markers and cytokines of dendritic cells harvested from cord blood. Clin. Diagnost. Lab. Immunol. 11(4), 686-690 (2004).
94. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst. Rev. 2, CD003048 (2004).
95. Mccartney AL, Wenzhi W, Tannock GW. Molecular analysis of the composition of the bifidobacterial and Lactobacillus microflora of humans. Appl. Environ. Microbiol. 62(12), 4608-4613 (1996).
96. Tynkkynen S, Singh KV, Varmanen P. Vancomycin resistance factor of Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Int. J. Food Microbiol. 41(3), 195-204 (1998).
97. Frossard CP, Steidler L, Eigenmann PA. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J. Allergy Clin. Immunol. 119(4), 952-959 (2007).
98. Ruszczynski M, Radzikowski A, Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment. Pharmacol. Ther. 28(1), 154-161 (2008).
99. Correa NB, Peret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J. Clin. Gastroenterol. 39(5), 385-389 (2005).
100. Jirapinyo P, Densupsoontorn N, Thamonsiri N, Wongarn R. Prevention of antibioticassociated diarrhea in infants by probiotics. J. Med. Assoc. Thailand 85(Suppl. 2), S739-S742 (2002).
101. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J. Pediatr. 135(5), 564-568 (1999).
102. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J. Tropical Pediatr. 50(4), 234-236 (2004).
103. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 21(5), 583-590 (2005).
104. Billoo AG, Memon MA, Khaskheli SA et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J. Gastroenterol. 12(28), 4557-4560 (2006).
105. Binns CW, Lee AH, Harding H, Gracey M, Barclay DV. The CUPDAY study: prebioticprobiotic milk product in 1-3-year-old children attending childcare centres. Acta Paediatr. 96(11), 1646-1650 (2007).
106. Pedone CA, Arnaud CC, Postaire ER, Bouley CF, Reinert P. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int. J. Clin. Pract. 54(9), 568-571 (2000).